Bachem Holding AG (BANB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Bachem Holding AG (Bachem) is a company specialising in the development and manufacture of peptides and oligonucleotides. The company offers products that include peptides for research, clinical development, and commercial application, oligonucleotides, custom synthesis, catalog peptides, peptide APIs, amino acid derivatives, cosmetic peptides, peptides for medical devices, and oligonucleotide APIs. Its products are used for the treatment of various conditions such as cardiovascular diseases, metabolic disorders, cancer and infectious diseases, among others. The company provides API manufacturing, process development, regulatory support, custom synthesis, project management and other analytical services. The company's products are utilised by customers in various industries for medical and scientific applications. Bachem operates internationally with locations in Europe, the US, and Asia, targeting global markets. Bachem is headquartered in Bubendorf, Switzerland.Bachem Holding AG Key Recent Developments
- Jul 03, 2026: Bachem and Novo Nordisk Redesign SPPS for Green Chemistry
- May 05, 2026: Bachem Announces Changes to the Corporate Executive Committee
- Apr 24, 2026: Bachem Inaugurates Building K in Bubendorf to Expand Large-Scale API Production
- Mar 12, 2026: Bachem Reports Sales Growth and Sustained High Profitability
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
- NovoCure Ltd Company Overview
- NovoCure Ltd Company Snapshot
- NovoCure Ltd Pipeline Products and Ongoing Clinical Trials Overview
- NovoCure Ltd - Pipeline Analysis Overview
- Business Description
- NovoCure Ltd - Key Facts
- NovoCure Ltd - Major Products and Services
- NovoCure Ltd Pipeline Products by Development Stage
- NovoCure Ltd Ongoing Clinical Trials by Trial Status
- NovoCure Ltd Pipeline Products Overview
- Maxpoint Treatment Planning Software
- Maxpoint Treatment Planning Software Product Overview
- Next Gen Field Generator
- Next Gen Field Generator Product Overview
- NovoTTF-100M System
- NovoTTF-100M System Product Overview
- NovoTTF-200A - Small Cell Lung Cancer
- NovoTTF-200A - Small Cell Lung Cancer Product Overview
- NovoTTF-200T - Advanced Non-Small Cell Lung Cancer
- NovoTTF-200T - Advanced Non-Small Cell Lung Cancer Product Overview
- NovoTTF-200T - Advanced Non-Small Cell Lung Cancer Clinical Trial
- NovoTTF-200T - Pancreatic Cancer
- NovoTTF-200T - Pancreatic Cancer Product Overview
- NovoTTF-200T - Pancreatic Cancer Clinical Trial
- Optune - Brain Metastasis
- Optune - Brain Metastasis Product Overview
- Optune - Brain Metastasis Clinical Trial
- Optune - Breast Cancer
- Optune - Breast Cancer Product Overview
- Optune - Cervical Cancer
- Optune - Cervical Cancer Product Overview
- Optune - Colorectal Carcinoma
- Optune - Colorectal Carcinoma Product Overview
- Optune - Ependymoma
- Optune - Ependymoma Product Overview
- Optune - Gliosarcoma
- Optune - Gliosarcoma Product Overview
- Optune - Liver Cancer
- Optune - Liver Cancer Product Overview
- Optune - Malignant Melanoma
- Optune - Malignant Melanoma Product Overview
- Optune - Medulloblastoma
- Optune - Medulloblastoma Product Overview
- Optune - Meningioma
- Optune - Meningioma Product Overview
- Optune - Non-Small Cell Lung Cancer
- Optune - Non-Small Cell Lung Cancer Product Overview
- Optune - Ovarian Cancer
- Optune - Ovarian Cancer Product Overview
- Optune - Pediatric Glioma
- Optune - Pediatric Glioma Product Overview
- Optune - Pediatric Glioma Clinical Trial
- Optune - Renal Adenocarcinoma
- Optune - Renal Adenocarcinoma Product Overview
- Optune - Small Cell Lung Cancer
- Optune - Small Cell Lung Cancer Product Overview
- Optune - Torso Array
- Optune - Torso Array Product Overview
- Optune - Torso Array Clinical Trial
- Optune - Urinary Transitional Cell Carcinoma
- Optune - Urinary Transitional Cell Carcinoma Product Overview
- Optune Pax
- Optune Pax Product Overview
- Optune Pax Clinical Trial
- Optune Plus Bevacizumab - Recurrent Glioblastoma
- Optune Plus Bevacizumab - Recurrent Glioblastoma Product Overview
- Optune Plus Bevacizumab - Recurrent Glioblastoma Clinical Trial
- Optune With Marizomib And Temozolomide - Glioblastoma
- Optune With Marizomib And Temozolomide - Glioblastoma Product Overview
- Optune With Pembrolizumab And Temozolomide
- Optune With Pembrolizumab And Temozolomide Product Overview
- Optune With Pembrolizumab And Temozolomide Clinical Trial
- NovoCure Ltd - Key Competitors
- NovoCure Ltd - Key Employees
- NovoCure Ltd - Key Employee Biographies
- NovoCure Ltd - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- NovoCure Ltd, Recent Developments
- Jul 13, 2026: NovoCure Receives Humanitarian Device Exemption (HDE) For Optune Lua (NovoTTF-100L System)
- Jul 01, 2026: Novocure Reports Second Quarter 2026 Financial Results
- Jul 01, 2026: Novocure receives CE mark for Optune Pax device
- Jun 18, 2026: Novocure’s Optune Gio fails to show benefit at earlier stage
- Apr 01, 2026: Novocure to Report Q1 2026 Financial Results
- Mar 09, 2026: NovoCure Recieves an additional Humanitarian Device Exemption Clearance for Optune Lua (NovoTTF-100L System)
- Mar 02, 2026: Novocure Announces Optune Lua Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
- Feb 27, 2026: Novocure Management To Attend 2026 Leerink Global Healthcare Conference
- Feb 24, 2026: Tumor Treating Fields (TTFields) Therapy to Be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)
- Feb 22, 2026: NovoCure Obtains PMA Approval for Optune Pax
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- NovoCure Ltd Pipeline Products and Ongoing Clinical Trials Overview
- NovoCure Ltd Pipeline Products by Equipment Type
- NovoCure Ltd Pipeline Products by Indication
- NovoCure Ltd Ongoing Clinical Trials by Trial Status
- NovoCure Ltd, Key Facts
- NovoCure Ltd, Major Products and Services
- NovoCure Ltd Number of Pipeline Products by Development Stage
- NovoCure Ltd Pipeline Products Summary by Development Stage
- NovoCure Ltd Ongoing Clinical Trials by Trial Status
- NovoCure Ltd Ongoing Clinical Trials Summary
- Maxpoint Treatment Planning Software - Product Status
- Maxpoint Treatment Planning Software - Product Description
- Next Gen Field Generator - Product Status
- Next Gen Field Generator - Product Description
- NovoTTF-100M System - Product Status
- NovoTTF-100M System - Product Description
- NovoTTF-200A - Small Cell Lung Cancer - Product Status
- NovoTTF-200A - Small Cell Lung Cancer - Product Description
- NovoTTF-200T - Advanced Non-Small Cell Lung Cancer - Product Status
- NovoTTF-200T - Advanced Non-Small Cell Lung Cancer - Product Description
- NovoTTF-200T - Advanced Non-Small Cell Lung Cancer - A Feasibility Study to Evaluate the Addition of Tumor Treating Fields to Treatment of Locally Advanced Stage III NSCLC
- NovoTTF-200T - Advanced Non-Small Cell Lung Cancer - LUNAR-2: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab and Platinum-based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
- NovoTTF-200T - Advanced Non-Small Cell Lung Cancer - Phase 0 Trial of Pre-operative Tumor Treating Fields in Patients with Resectable Lung Cancer
- NovoTTF-200T - Pancreatic Cancer - Product Status
- NovoTTF-200T - Pancreatic Cancer - Product Description
- NovoTTF-200T - Pancreatic Cancer - A Phase II Study of Peri-Operative NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
- Optune - Brain Metastasis - Product Status
- Optune - Brain Metastasis - Product Description
- Optune - Brain Metastasis - Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma
- Optune - Breast Cancer - Product Status
- Optune - Breast Cancer - Product Description
- Optune - Cervical Cancer - Product Status
- Optune - Cervical Cancer - Product Description
- Optune - Colorectal Carcinoma - Product Status
- Optune - Colorectal Carcinoma - Product Description
- Optune - Ependymoma - Product Status
- Optune - Ependymoma - Product Description
- Optune - Gliosarcoma - Product Status
- Optune - Gliosarcoma - Product Description
- Optune - Liver Cancer - Product Status
- Optune - Liver Cancer - Product Description
- Optune - Malignant Melanoma - Product Status
- Optune - Malignant Melanoma - Product Description
- Optune - Medulloblastoma - Product Status
- Optune - Medulloblastoma - Product Description
- Optune - Meningioma - Product Status
- Optune - Meningioma - Product Description
- Optune - Non-Small Cell Lung Cancer - Product Status
- Optune - Non-Small Cell Lung Cancer - Product Description
- Optune - Ovarian Cancer - Product Status
- Optune - Ovarian Cancer - Product Description
- Optune - Pediatric Glioma - Product Status
- Optune - Pediatric Glioma - Product Description
- Optune - Pediatric Glioma - Feasibility Trial of Optune for Children With Recurrent or Progressive Supratentorial High-Grade Glioma or Ependymoma, and Feasibility and Efficacy Trial of Optune in Conjunction With Radiation Therapy for Children With Newly Diagnosed DIPG
- Optune - Renal Adenocarcinoma - Product Status
- Optune - Renal Adenocarcinoma - Product Description
- Optune - Small Cell Lung Cancer - Product Status
- Optune - Small Cell Lung Cancer - Product Description
- Optune - Torso Array - Product Status
- Optune - Torso Array - Product Description
- Optune - Torso Array - A Clinical Usability Study of Torso Array to Improve Patient Comfort for All Torso and Abdominal Indications
- Optune - Urinary Transitional Cell Carcinoma - Product Status
- Optune - Urinary Transitional Cell Carcinoma - Product Description
- Optune Pax - Product Status
- Optune Pax - Product Description
- Optune Pax - Phase 2 Trial of Ablative MRI-guided Stereotactic Body Radiation Therapy and Tumor Treating Fields for Locally Advanced Pancreas Cancer
- Optune Plus Bevacizumab - Recurrent Glioblastoma - Product Status
- Optune Plus Bevacizumab - Recurrent Glioblastoma - Product Description
- Optune Plus Bevacizumab - Recurrent Glioblastoma - A Phase II Trial of Tumor Treating Fields (TTfields) Concomitant with Radiosurgery for the Treatment of Recurrent, Bevacizumab-naïve Glioblastoma
- Optune With Marizomib And Temozolomide - Glioblastoma - Product Status
- Optune With Marizomib And Temozolomide - Glioblastoma - Product Description
- Optune With Pembrolizumab And Temozolomide - Product Status
- Optune With Pembrolizumab And Temozolomide - Product Description
- Optune With Pembrolizumab And Temozolomide - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune® (TTFields, 200 kHz) Concomitant With Maintenance Temozolomide and Pembrolizumab Versus Optune® Concomitant With Maintenance Temozolomide and Placebo for the Treatment of Newly Diagnosed Glioblastoma (EF-41/KEYNOTE D58).
- Optune With Pembrolizumab And Temozolomide - Phase II, Single Arm, Historically Controlled Study Testing the Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune) Plus Pembrolizumab in Patients with Newly Diagnosed Glioblastoma (2-THE-TOP)
- NovoCure Ltd, Key Employees
- NovoCure Ltd, Key Employee Biographies
- NovoCure Ltd, Other Locations
- NovoCure Ltd, Subsidiaries
- Glossary
- NovoCure Ltd Pipeline Products by Equipment Type
- NovoCure Ltd Pipeline Products by Development Stage
- NovoCure Ltd Ongoing Clinical Trials by Trial Status
